Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer.
about
Quality of life issues in men undergoing androgen deprivation therapy: a reviewGonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancerMemory and cancer: a review of the literatureBody composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study.Clinical significance of androgen secretion disorders in men with a malignancy.Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomesA pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy.Efficacy of walking exercise in promoting cognitive-psychosocial functions in men with prostate cancer receiving androgen deprivation therapy.Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art.Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study.Management of complications of androgen deprivation therapy in the older man.Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy.Clinically localised prostate cancer.Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorderAndrogen deprivation therapy toxicity and management for men receiving radiation therapyThe impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States.Association of Androgen Deprivation Therapy With Depression in Localized Prostate CancerImpact of androgen deprivation therapy on cardiovascular disease and diabetes.Challenges of managing elderly men with prostate cancer.Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.Testosterone replacement therapy improves the health-related quality of life of men diagnosed with late-onset hypogonadism.The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.The side effects of hormonal therapy at the patients with prostate cancerTNF is necessary for castration-induced prostate regression, whereas TRAIL and FasL are dispensable.Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.Discrepancies on the association between androgen deprivation therapy for prostate cancer and subsequent dementia: meta-analysis and meta-regression.Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach
P2860
Q27002887-15947469-8D2D-4D88-A3D5-E7F6F2A881AAQ33351115-39F9CE56-F4D8-461A-8AA3-76E82CCECA79Q33663544-7D9C9953-1606-4216-BB8D-BD1748E127C3Q33677118-4DAA4C0C-2C83-423A-87F1-9CB1B3A3A8E7Q33840617-14FEB171-6ED0-4500-81B7-094D44A55EA8Q33890406-BCE67953-9CED-4658-BC11-42B84555EC9FQ34205158-5216DE80-54A4-449A-BF04-5730F6869306Q34356705-F60C069B-BF42-439E-BD34-1D61A9733461Q34417815-5C484CD3-5FB1-4BC6-9942-5F6BE3A7F77BQ34778958-BC90679B-FC16-4BBE-A56C-8A3FA7FDC6FAQ34782101-432E06C0-BB06-4E68-BE18-F29A73791BA1Q34823216-597DE93E-C1A4-474A-A772-432E7948BEF7Q35166972-B3DCD2CA-FE86-49D6-BECD-1D45F5D477B8Q35754343-DD99C2B8-7207-42BB-AFA3-8555CC1C07AAQ36295478-0C27076A-6D69-498B-A9DF-63E325A3A556Q36530136-36C20A1F-675D-4833-B79D-9C794C51E4C3Q36686892-642871B5-6D75-4557-9471-BE169D6009F4Q37137956-5ADDDA1E-3B23-437F-99D8-3EDFFD0AD56BQ37583719-48759B4E-0549-4FAD-BAD3-4EE16E5BFF11Q38211358-BA6FBD01-9B22-4D9B-8D16-2A3CA934AAEFQ38608309-E0838F56-FB67-457D-8660-C0A57177B26CQ38634958-3D866576-6013-45E0-857E-AFF6E3FE38B6Q41566002-129F16DA-1ED1-43A6-B555-DD90B8B6D89AQ41859896-05E8A515-5C87-4AF6-919C-85E9EAD4DB8FQ42016370-69CB64D5-4939-44F3-A939-A9A6B10D28C1Q42026695-EAD0FEDD-1839-466C-81DC-F81738C8FA4EQ42700699-BA9CCACB-14C1-48EE-B6D9-06B7B53C5A0DQ57108196-8F5773DE-39B3-49F3-8F56-E1EEDA4D664E
P2860
Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Risk of the "androgen deprivat ...... privation for prostate cancer.
@ast
Risk of the "androgen deprivat ...... privation for prostate cancer.
@en
type
label
Risk of the "androgen deprivat ...... privation for prostate cancer.
@ast
Risk of the "androgen deprivat ...... privation for prostate cancer.
@en
prefLabel
Risk of the "androgen deprivat ...... privation for prostate cancer.
@ast
Risk of the "androgen deprivat ...... privation for prostate cancer.
@en
P2093
P2860
P1476
Risk of the "androgen deprivat ...... privation for prostate cancer.
@en
P2093
James S Goodwin
Jean L Freeman
Vahakn B Shahinian
Yong-Fang Kuo
P2860
P304
P356
10.1001/ARCHINTE.166.4.465
P407
P577
2006-02-01T00:00:00Z